News
Immunome Reports Third Quarter 2020 Financial Results and Significant Progress
– Completed $44.9M IPO in October –
– Identified COVID 19 Neutralizing antibodies –
– Significant progress made on lead programs, including IMM-BCP-01 for the treatment of COVID-19 in collaboration with US Department of Defense –
Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases
Ossianix to Present Preclinical Data Demonstrating Best-in-Class Blood Brain Barrier Delivery in Non-Human Primates by Single Domain VNAR Antibodies
– Over 30-Fold Increase in Hippocampus Observed –
– Results Promising for Delivery of Biological Therapeutics for Neurologic Diseases –
– Results to be Presented at Protein & Antibody Engineering Summit Europe –
Aptar Pharma Acquires the Assets of Cohero Health, a Digital Respiratory Health Company, Further Expanding its Capabilities in Digital Health
Mebias Discovery Receives Grant from NIDA to Advance MEB‑1170 as an Analgesic Drug Candidate for the Prevention and Treatment of Opioid Use Disorder
Grant to Fund IND Enabling and Phase 1 Clinical Trials
Preclinical Data Demonstrates MEB‑1170 Lacks Dangerous Side Effects Including Respiratory Depression and Opioid Abuse Potential
Annovis Bio Resumes Treatment of Patients in Ongoing Phase 2a Study in Alzheimer’s Disease After COVID-Related Delay
Relmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones
Envara Health Launches Encala® to Enhance Fat Absorption and Provide Healthy Calories for Patients with Cystic Fibrosis
New, innovative therapy brings breakthrough science and clinical evidence to nutrition
Helps patients with malabsorption meet their weight and nutritional needs